Deutsche Bank Ag\ Ventyx Biosciences, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 30,328 shares of VTYX stock, worth $70,664. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,328

Previous 17,725 71.1%

Holding current value

$70,664

Previous $40,000 65.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.85 - $3.2 $23,315 - $40,329	12,603 Added 71.1%	30,328 $66,000
Q2 2024 Aug 14, 2024	SELL	$2.31 - $5.59 $12,423 - $30,063	-5,378 Reduced 23.28%	17,725 $40,000
Q1 2024 May 15, 2024	BUY	$1.9 - $10.13 $28,207 - $150,389	14,846 Added 179.8%	23,103 $127,000
Q4 2023 Feb 14, 2024	SELL	$2.08 - $31.18 $194,794 - $2.92 Million	-93,651 Reduced 91.9%	8,257 $20,000
Q3 2023 Nov 09, 2023	SELL	$29.8 - $40.3 $415,710 - $562,185	-13,950 Reduced 12.04%	101,908 $3.54 Million
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $553,539 - $767,349	19,402 Added 20.11%	115,858 $3.8 Million
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $2.46 Million - $3.89 Million	83,375 Added 637.37%	96,456 $3.23 Million
Q4 2022 Feb 13, 2023	BUY	$24.16 - $36.38 $75,282 - $113,360	3,116 Added 31.27%	13,081 $428,000
Q3 2022 Nov 14, 2022	SELL	$12.64 - $38.7 $15,028 - $46,014	-1,189 Reduced 10.66%	9,965 $348,000
Q2 2022 Aug 11, 2022	BUY	$11.95 - $18.75 $65,593 - $102,918	5,489 Added 96.89%	11,154 $137,000
Q1 2022 May 13, 2022	SELL	$10.0 - $19.98 $6,800 - $13,586	-680 Reduced 10.72%	5,665 $77,000
Q4 2021 Feb 11, 2022	BUY	$14.2 - $23.07 $90,099 - $146,379	6,345 New	6,345 $126,000

Others Institutions Holding VTYX

# of Institutions

125

Shares Held

52.9M

Call Options Held

35.3K

Put Options Held

83K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $132M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account